2023 World Conference on Lung Cancer (Posters)-EP09.02. Operative and Mid-Term Oncologic Outcomes of the Surgery as a Form of Local Consolidation for Oncogenic-Driven Advanced NSCLC

EP09.02. Operative and Mid-Term Oncologic Outcomes of the Surgery as a Form of Local Consolidation for Oncogenic-Driven Advanced NSCLC - PDF(Slides)

Back to course

Pdf Summary

This study focused on the use of surgery as a form of local consolidation for oncogenic-driven advanced non-small cell lung cancer (NSCLC) after targeted therapy. The objective was to investigate the peri-operative and mid-term oncologic outcomes of this approach. The study included 74 patients who received pulmonary resection for stage IIIB-C or IV NSCLC after targeted therapy. The median postoperative follow-up period was 27.5 months.<br /><br />The results showed that the 5-year overall survival rate after initial treatment was 68.2%, while the 3-year overall survival rate after surgery was 74.5%. The 3-year progression-free survival rate after surgery was 43.6%, with a median progression-free survival of 24.7 months. Patients with ALK/ROS1 mutations had a better prognosis in terms of progression-free survival and targeted therapy duration compared to patients with EGFR mutations.<br /><br />The study also found that the median peri-operative targeted therapy duration was 30.2 months, which was longer than what was previously reported in the literature. Additionally, a significant number of patients (56.7%) still maintained peri-operative targeted therapy at the time of follow-up.<br /><br />Based on these results, the authors concluded that pulmonary resection after targeted therapy for advanced NSCLC was feasible and showed promising mid-term oncologic outcomes in terms of avoiding or delaying progression. However, they emphasized the need for further trials to study the long-term benefits of pulmonary resection on oncologic outcomes after targeted therapy.<br /><br />Overall, this study contributes to the growing knowledge about the role of surgery as a local consolidation therapy for advanced oncogenic-driven NSCLC and highlights its potential benefits in terms of patient survival and disease progression.

Asset Subtitle

Byung Jo Park

Meta Tag

Speaker Byung Jo Park

Topic Metastatic NSCLC: Local Therapies - Integration With Systemic Therapies

Keywords

surgery

local consolidation

oncogenic-driven

non-small cell lung cancer

NSCLC

targeted therapy

peri-operative outcomes

mid-term oncologic outcomes

overall survival rate

progression-free survival rate